Bleb Vascularity Change After Subconjunctival Injection Bevacizumab
This trial is active, not recruiting.
|Conditions||bleb vascularity, conjunctival scarring|
|Sponsor||Capital Medical University|
|Start date||December 2008|
|End date||March 2009|
|Trial size||30 participants|
|Trial identifier||NCT00815594, 2008TR-LX-001|
The occurrence of conjunctival scarring finally leads to the obstruction of the fistula tract created by the filtering surgery. Vascular endothelial growth factor is thought to be a key role in the formation of conjunctival scar, which play a pivotal role in the wound-healing process. So it seems that the recombinant human anti-VEGF antibody could inhibit angiogenesis, and reduce the conjunctival vascular formation in the wound-healing process after glaucoma filtering surgery.
|Endpoint classification||efficacy study|
|Intervention model||single group assignment|
bleb vascular change
time frame: one day, one week, one month
Male or female participants from 18 years up to 80 years old.
Inclusion Criteria: - Glaucoma patients after trabeculectomy whose bleb is hyperaemia Exclusion Criteria: - Affected eye has normal IOP - Not allergic with Avastin
|Official title||Bleb Vascularity Change After Subconjunctival Injection of Bevacizumab|
|Principal investigator||Liu Xuan, M.D.|
Call for more information